Live Report from ASH:
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

AudioMedica News
AudioMedica News
Live Report from ASH:
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma
Loading
/
Anton Hagenbeek
Anton Hagenbeek

ANTON HAGENBEEK, University Medical Centre Utrecht
For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH meeting in Atlanta while George Canellos provided comment.

Live Report from ASH:<br />Ibritumomab Provides Benefit in Patients with Follicular Lymphoma



LISTEN

[audio:https://www.audiomedica.com/podcasting/oncology/071209_anton_hagenbeek.mp3]

Further reading

Sign up for AudioMedica.com news

* = required field
Speciality